Becton Dickinson & Company Acquires Edwards Lifescience’s Critical Care Business for .2 Billion
In a significant move, Becton Dickinson & Company has announced the acquisition of Edwards Lifescience’s Critical Care Business for .2 billion. This acquisition marks a strategic decision for both companies and is expected to be finalized before the end of the year.
Prior to this acquisition, Edwards Lifescience had revealed plans to spin off its Critical Care Business late last year. The reasoning behind this move was to allow the company to shift its focus towards its structural heart offerings, particularly transcatheter aortic valve replacement procedures.
BD highlighted Critical Care as a key player in advanced patient monitoring with sophisticated AI algorithms. The company emphasized that Critical Care pioneered the hemodynamic monitoring category and its solutions are currently utilized in over 10,000 hospitals worldwide. These solutions provide real-time insights into the cardiovascular condition of critically ill patients, ultimately leading to improved outcomes.
With approximately 4,500 employees primarily based in Irvine, California, Critical Care generated over 0 million in revenue in 2023. BD views this acquisition as an opportunity to enhance its portfolio of smart connected care solutions, complemented by Critical Care’s innovative monitoring technologies and AI-enabled clinical decision tools.
Tom Polen, the chairman, CEO, and president of BD, expressed optimism about the acquisition, stating that it aligns well with BD’s core innovation and business strategies. He believes that the combination of both companies will unlock various avenues for growth and value creation, ultimately benefitting shareholders.
The acquisition of Critical Care by Becton Dickinson & Company signifies a strategic move to strengthen its position in the healthcare industry and expand its offerings in advanced patient monitoring and AI technologies.
